Picture of Trans Lux logo

TNLX — Trans Lux News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyHighly SpeculativeMicro Cap

Telix Pharma hits record high as co edges closer to product launch in Europe

** Shares of Telix Pharmaceuticals Ltd  TLX.AX , which
specialises in using radiology to treat cancer, climb as much as
4.8% to an all-time high of A$7.86
    ** Co says its marketing authorisation application
submission in Europe for registering TLX's investigational
product Illuccix has progressed to the final stage of regulatory
assessment  urn:newsml:reuters.com:*:nASX92WvQl
    ** Telix expects a decision by no later than March 23, 2022
    ** Telix's lead product Illuccix, being developed for
prostate cancer imaging, has been approved by the Australian
Therapeutic Goods Administration and accepted for filing by the
U.S. Food and Drug Administration  urn:newsml:reuters.com:*:nL4N2RT06R
    ** More than 554,600 shares change hands, compared with the
30-day average volume of ~428,300 shares 
    ** Stock up 98.4% this year, as of last close, compared with
an 11.8% increase in the ASX All Ordinaries Index  .AORD  

 

 (Reporting by Roushni Nair in Bangalore)
 ((Roushni.Nair@thomsonreuters.com))

Recent news on Trans Lux

See all news